Back to top
more

Masimo (MASI)

(Real Time Quote from BATS)

$163.92 USD

163.92
126,674

+3.07 (1.91%)

Updated Nov 13, 2024 01:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (65 out of 250)

Industry: Medical - Instruments

Zacks News

Can Overall Growth Drive Thermo Fisher (TMO) Q3 Earnings?

Thermo Fisher's (TMO) steadily strong analytical instrument business flaunts higher global demand.

Will Boston Scientific's (BSX) Q3 Earnings Reflect Overall Gain?

We are optimistic about the IC business that will help Boston Scientific (BSX) maintain impressive global growth, owing to an innovative portfolio and robust commercial teams.

Can Abbott's (ABT) Steady Overall Growth Aid Q3 Earnings?

Abbott (ABT) is consistently well-placed on a healthy growth trajectory within its Diabetes Care business for the past few quarters.

Here's Why You Should Invest in GNC Holdings (GNC) Right Now

GNC Holdings (GNC) registers strong performance in e-commerce business and International segment. In fact, the company is putting an all-out effort to strengthen its international presence.

    What's in Store for Cerner (CERN) This Earnings Season?

    Cerner's (CERN) third-quarter 2018 results are likely to be hurt by soft segmental results; guidance promising.

      Will Instruments Drive Intuitive Surgical (ISRG) Q3 Earnings?

      Strong prospects in the Instruments and Accessories segment to drive Intuitive Surgical???s (ISRG) top line in the third quarter of 2018.

        Amedisys to Buy Compassionate Care Hospice, Share Price Down

        Amedisys (AMED) adopts initiatives to boost hospice business. It expects to become the third-largest hospice provider in America with the latest buyout.

          Varian Medical (VAR) Q4 Earnings: Is a Surprise in Store?

          Solid prospects in the Oncology segment to boost Varian Medical's (VAR) top-line performance in the fourth quarter of fiscal 2018.

          What's in Store for Express Scripts' (ESRX) Q3 Earnings?

          Express Scripts (ESRX) likely to see soft PBM revenues in the third quarter of 2018; guidance strong.

            Quest Diagnostics Boosts Health & Wellness, Acquires Provant

            Quest Diagnostics' (DGX) Provant Health acquisition is in line with its 'accelerate growth' strategy.

            Can Masimo (MASI) Keep the Earnings Surprise Streak Alive?

            Masimo (MASI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

            QIAGEN Introduces New RNA-seq Library Preparation Solutions

            QIAGEN (QGEN) adopts initiatives to boost the NGS portfolio.

            Wright Medical (WMGI) Takes Over Cartiva for $435M in Cash

            The Cartiva buyout will boost Wright Medical's (WMGI) Lower Extremities business.

            Walgreens (WBA) Q4 Earnings Top Estimates, Revenues Lag

            Walgreens' (WBA) Retail Pharmacy USA division witnesses comparable prescription growth and benefits from a strong retail prescription market.

            Baxter & ASPEN Launch PN Tools to Boost Clinical Nutrition

            Baxter (BAX) and ASPEN's SmartPN lends the company a competitive edge in the MedTech space.

            BioScrip Grows on CORE Plan, Reimbursement Issues Persist

            BioScrip (BIOS) progresses well on the back of its new multi-faceted CORE plan to improve its financial position.

            Genomic Health's Test Gets Favored by New NCCN Guidelines

            Genomic Health (GHDX) forges ahead with the development of Oncotype DX Breast Recurrence Score test.

            Express Scripts Introduces Medicare PDP Offerings for 2019

            Express Scripts' (ESRX) Medicare PDP to initiate coverage from Jan 1, 2019. The plan includes Walmart along with CVS Pharmacy and the Kroger Family of Pharmacies.

            Accuray's (ARAY) Radixact System Used First Time in Germany

            Accuray's (ARAY) flagship radiotherapy systems have lucrative prospects.

            Here's Why You Should Buy HealthEquity (HQY) Stock Right Now

            Strong presence in the HSA space and a solid guidance for fiscal 2019 make HealthEquity (HQY) a promising investment pick.

            Here's Why You Should Invest in Boston Scientific Stock Now

            Boston Scientific (BSX) is coming up with better-than-expected earnings and revenue performances on the back of growth across all business lines and geographies.

            Edwards Begins US CENTERA Study, Reintroduces Valve in Europe

            Edwards (EW) is recommencing commercial introduction of CENTERA valve in Europe after making certain minor modification to CENTERA's delivery system.

            Here's Why You Should Hold Ecolab Stock in Your Portfolio

            Despite fluctuations in the cost of raw materials, Ecolab (ECL) to gain from strong performance in the Global Industrial segment.

              The Zacks Analyst Blog Highlights: Masimo, Medtronic, Garmin and DexCom

              The Zacks Analyst Blog Highlights: Masimo, Medtronic, Garmin and DexCom

              Here's Why You Should Invest in Genomic Health (GHDX) Now

              Genomic Health (GHDX) continues to see increasing private coverage for the Oncotype DX GPS test.